From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
FMF(10) | CAPS(24) | TRAPS(11) | HIDS/MKD(3) | Total (48) | |
---|---|---|---|---|---|
M/F | 5/5 | 10/14 | 5/6 | 0/3 | 20/28 |
Age (years old) | 4,5-38 | 1,5-9 | 4,5-21 | 4-17 | 1,5-38 |
The duration of disease (y) | 1month-15,5 | 1,5-44 | 3 months -21 | 3,5-15,5 | 1 month -44 |
Etanercept | 3 | - | 1 | - | 4 |
Аdalimumab | 2 | - | 1 | - | 3 |
Tocilizumab | 1 | 2 | 3 | 1 | 7 |
Сanakinumab | 6 | 18 | 8 | 1 | 33 |
Аnakinra | 1 | 8 | - | 1 | 10 |